A new Horizon has been opened for Diabetes treatment. Concord Pharmaceuticals Ltd. proudly introduced new oral antidiabetic drug Dapazin (Dapagliflozin), for the first time in Bangladesh which may reduce the insulin dependency in millions of diabetic patients in future.
Concord Pharmaceuticals has launched US FDA Approved latest anti diabetic drug Dapagliflozin as brand name Dapazin (5 mg Tablet).
The Legend Diabetes specialist & The President of Bangladesh Diabetic Association Prof. Dr. A K Azad Khan inaugurated the launching of Dapazin on 28 Aug ’15 in Dhaka Regency Hotel & Resort. Major General Md. Mustafizur Rahman, Directorate General of Drug Administration (DGDA) was present as special guest.
The Key note speaker Prof. Dr. M A Hasanat, Chairman, Department of Endocrinology, Bangabandhu Sheikh Mujib Medical University (BSMMU) & Assistant Prof. Dr. Shahjada Selim has delivered the clinical presentation . Prof. Dr. Hajera Mahtab, Prof. Dr. M. A. Mannan, Prof. Dr. Laique Ahamed Khan, Prof. Dr. Abdul Mannan Sarker and Prof. Dr. Md. Nazrul Islam Siddiqui was present as Expert Panel.
The Specialist Doctors Informed that Dapazin may help to control Blood glucose with additional reduction of hypertension and body weight. They also added that in near future Dapazin may reduce the insulin dose and dependency of diabetic patients. There are more than 200 Diabetic specialists and other doctors from different corner of the country were present in the program. Chairman, Md. Faizur Rahman and Managing Director, Md. Saidur Rahman of Concord Pharmaceuticals Ltd welcomed the entire invited guest in the program.